Canada’s legal cannabis sector saw TRIPLE-DIGIT growth in 2020, more than doubling to $2.6 billion.
Ahead of this surge, Canadian regulators began to approve new products such as edibles, beverages and vaping products, known as cannabis 2.0. It’s as the researchers at Brightfield Group are stating unequivocally: “Cannabis 2.0 is here”.
But even as the market adjusts to cannabis 2.0, Bruce Linton, co-founder of the world’s largest cannabis company Canopy Growth (NASDAQ:CGC) (TSX:WEED), was already prophesying about the next wave—Cannabis 3.0.
Cannabis 3.0 takes consumption one step further, beyond consumables and into the health sector, with balms, ointments, lotions, and many more products designed to make life better.
At the centre of both cannabis 2.0 and 3.0 are plant-based extraction experts:
This well-connected Canadian-based company is currently making their much-anticipated entry into the lucrative United States market, signalling an incredible opportunity that we believe is the BEST play in the extraction game.
Pure Extracts is a plant-based extraction company focused on cannabis, hemp, functional mushrooms, and the rapidly emerging psychedelic sector from a state-of-the-art processing facility located just north of Whistler, British Columbia.
Expert analysts across the sector are searching for their winner in the space, including Matthew Timane, senior market strategist at Schaeffer’s Investment Research, who is already preparing his followers for the bull market forming around this cannabis 2.0 era.
Below is a screenshot captured from a March 26, 2021 report from Fundamental Research on Pure Extracts Technologies Corp. that gives it a fair market value of almost 100% higher than its current PPS.
Here’s the link to the full report: https://www.researchfrc.com/pure-extracts-technologies-corp-cse-pull-otc-prxtf-xfra-a2qjaj-extracts-company-positioned-for-cannabis-2-0-and-mushrooms-initiating-coverage/
Highly-Technical Leaders in Plant-Based Extraction
Nestled just north of the famous mountain resort community of Whistler, BC, is a centralized facility designed and built for Pure Extracts’ (OTC: PRXTF / CSE: PULL / XFRA: A2QJAJ) highly technical proprietary and white-labelled production.
Most recently, Pure Extracts is now entering the United States through an LOI signed with a publicly-traded Multi-State Operator (MSO) to create a joint-venture in order to install a cannabis and hemp extraction system in an existing Michigan facility.
The venture partners plan to build-out 2,600 sq. ft. of existing, under-utilized space in the MSO’s current facility, which is strategically located in central Michigan within a 2-hour drive of several major markets.
With over 5 years of volatile plant molecule extraction experience, the company has compiled a successful track record of creating multiple popular consumer packaged goods (CPG) products and brands.
Constantly building upon this experience, Pure Extracts has an undeniable first mover advantage, which it is already exploiting.
Through its cannabis and hemp extraction wing, the company is already servicing tolling agreements for customers, and has signed an exclusive Canadian and international license with Taste-T LLC, the manufacturer of the Fireball brand of gummies.
And as of September 25th, the company officially received its Health Canada Standard Processing license.
In Canada, Pure Extracts’ Whistler facility’s footprint is 10,000 sq ft, complete with a dedicated extraction room, vault, post-processing lab and packaging space including the important build-out of the psychedelic R&D space already under development in preparation for the company’s Dealer’s Licence, which is expected to be granted by Health Canada at the end of this year. All the while building towards EU-GMP standards for international distribution.
The operation relies on modern CO2 and ethanol extraction capabilities and processes including one of the first Vitals Cosolvent Injection Systems (CIS) anywhere in the world, while the entire facility was designed with growth in mind -it’s Easily Scalable.
Beyond Cannabis: Functional Mushrooms’ Market Breakthrough
Backed by billionaire investor Peter Thiel the COMPASS Pathways plc (NASDAQ:CMPS) back in 2018 received breakthrough therapy designation from the US Food and Drug Administration (FDA) on a psilocybin treatment.
Now doctors, therapists, and medical researchers are looking very seriously at these mushrooms and other psychedelics as being on the verge of clinically approved medicine. Currently tens of millions of dollars are being raised for subsequent research in a goal of impressing the FDA to grant approvals to even more psychedelic treatments.
Thiel went on to double down on this concept in 2010, investing in a second company in Germany called ATAI Life Sciences.
However, behind the scenes there are already opportunities for immense profits.
Right now, researchers are paying extremely large sums of money for very small trace amounts of the medicinal-grade psilocybin. In 2018, scientists who wanted to study psychedelic mushrooms would have to pay between $7,000 – $10,000 per gram– a high cost due in part to the processes involved in synthesizing a form of psilocybin that meets standards set by the FDA’s Good Manufacturing Practice (GMP).
The psilocybin renaissance is at the forefront of what’s being dub bed the “third wave” of psychedelics—which includes not only pharmaceutical grade drugs and treatments, but also closely managed microdosing which involves minute traces of these drugs so as to give all the benefits without the full psychedelic response.
But it’s not only psychedelic mushrooms that are being given a serious look in the wellness market. Rather than magic mushrooms, non-psilocybin mushrooms are giving rise to what’s being called “mushroom magic” by the mainstream media, as the latest mushroom health fad looks to have scientific backing.
Pure Extracts (OTC: PRXTF / CSE: PULL / XFRA: A2QJAJ) is leveraging the growing acceptance by mainstream science and the general public to further develop and commercialize functional and medicinal mushroom products on a global scale. To that end, the company has secured a reliable supply of organically grown psychedelic mushrooms through a LOI with British Columbia based ShroomBloom. But in order for new products to hit the market, first the ingredients must be extracted.
Plant-Based Extraction Market is in its Infancy
With a push for both herbal supplement and CPG products, along with pharmaceutical grade psychedelics, there appears to be a wide-open market in play.
The political and social landscape surrounding these medicinal products is rapidly shifting -mushrooms, psilocybin and psychedelics together.
Recently Johnson & Johnson’s (NYSE: JNJ) ketamine-based (another banned psychedelic drug) Spravato became the first promising new treatment for major depression to win approval in years—with 2024 sales projected to reach $1.3 billion.
Extraction isn’t limited just to fungi. There’s still demand for cannabis and hemp derived products, despite the appearance of the cannabis flower industry having gone up in smoke. In legal markets such as California, concentrates are outselling raw flower. Much like the functional mushrooms market, the full-spectrum cannabis market is massive market.
Pure Extracts (OTC: PRXTF / CSE: PULL / XFRA: A2QJAJ) uses sub and supercritical CO2 and ethanol methods to extract a much wider range of compounds to provide these benefits to consumers in vape cartridges or other formats. Full-spectrum cannabis oils differ from regular distillate, in that they’re more difficult to produce and require high-quality input materials, such as full bud, high-potency, terpene-rich flower since the taste more closely resembles the plant inputs.
Because of this, Pure Extracts (OTC: PRXTF / CSE: PULL / XFRA: A2QJAJ) can capitalize on full-spectrum cannabis oils as premium products, often sold at a higher margins. These come with a significant price premium, and a novelty that most cultivators can’t produce without assistance and expertise.
Couple this business model with the ability to extract psilocybin from mushrooms, and Pure Extracts (OTC: PRXTF / CSE: PULL/ XFRA: A2QJAJ ) will have secured TWO significant revenue streams from its state-of-the-art extraction capabilities
Pure Pulls: Nationally Recognized Brand
Pure Extracts’ (OTC: PRXTF / CSE: PULL / XFRA: A2QJAJ) Pure Pulls [JC1] is the first of its kind, as a nationally recognized brand, successfully developed with over 30 proprietary formulations in the traditional cannabis market. Pure Pulls illustrates best practice purity in manufactured products that meet or exceed quality expectations. This has led to the establishment of goodwill and repeat customers that exhibit strong brand loyalty.
This has been helped by steady brand equity awareness campaigns, developed through event sponsorship and ongoing product engagement. This has led to Pure Pulls growing and retaining its retail distributor reach, always with a renewal plan in place.
The company is also launching its Pure Mushrooms brand of functional wellness products in May through an online Amazon e-Commerce platform. Initial products include Reishi, Maitake and coming soon, Lion’s Mane.
Pure Extracts’ establishment ss a Best In Class Technology Investment, due to its Mass Production Capability. Now Pure Extracts has grown its brand longevity through product innovation and diversity, which will bolster the company’s product line of tinctures, vape pens and soft gel capsules -future product expansions will include edibles and topicals.
Business Line: Pure Cannabis & Hemp
Pure Extracts Corp. has signed its first of what it expects will be multiple tolling agreements for both cannabis (THC) and hemp (CBD) extracts.
But on top of that, the company has signed an exclusive Canadian & International license for a large US alcohol brand of gummies know as ‘Fireball’.
On September 25, 2020 Pure Extracts obtained its Health Canada Standard Processing License which allowed the company to start commissioning its equipment and start sourcing biomass for extraction.
The Ideal FACILITY
Designed for proprietary and white-labelled production, Pure Extracts’ (OTC: PRXTF / CSE: PULL / XFRA: A2QJAJ) centralized facility brings a unique advantage in the industry. Starting with its current facility that’s 10,000 sq ft, including the important build-out of the psychedelic R&D space already under development in preparation for the company’s Dealer’s Licence, which is expected to be granted by Health Canada at the end of this year. The goals of the upgrades are not only volume related, but ultimately to achieve EU-GMP standards for international distribution.
The facility utilizes modern CO2 and ethanol extraction capabilities and processes, and comes with a dedicated lab and packaging spaces. Strategically from the beginning, the Pure Extracts production facility was designed with growth in mind—it’s EASILY scalable.
Research & Development Strategy
Pure Extracts has signed an LOI with Psyence Group (CSE: PSYG) to collaborate on extraction techniques for psilocybin and formulation of medicinal products.
Psyence is one of the world’s first psychedelic mushroom companies operating a federally legal commercial cultivation and extraction facility in Southern Africa and possessing an experienced global team of doctors and scientists striving for breakthroughs in palliative care, neurology, neuroscience and drug development.
The Psyence Group sets the global standard for natural psychedelics. The executive team have international experience in the business of science and medicine and include global experts in palliative care, neurology, neuroscience and drug development. Psyence has built and operates one of the first federally licensed commercial psilocybin cultivation and production facilities. Psyence is pioneering the use of natural psilocybin for the long-term treatment of psychological trauma and its mental health consequences. Our global footprint spans multiple legal jurisdictions, through the provision of advanced models of psychedelic therapy and experience, as well as market leading functional mushroom brandsHow Pure Extracts Stacks Up to Extraction/ Psychedelics Peers
Pure Extracts (OTC: PRXTF / CSE: PULL/ XFRA: A2QJAJ) is not only a leader in extracts and extract-based CPGs, but the company has also signed a research and development deal with Dr. Alexander MacGregor at the Toronto Institute of Pharmaceutical Technology (TIPT) that secures a potential pipeline of new products, compounds and assets.
Because of this range, Pure Extracts is a bit trickier to measure against just one group of comparables. If you only compare with extracts companies, then you’re at risk of discounting the significant potential of the mushroom products and new psychedelics therapies. However, due to its significant tolling and licensing deals already signed it’s also not helpful to exclude cannabis extraction peers. So, below is a table that covers potential comparable companies across Pure Extracts’ range of strengths:
|Company||Symbol||Business||Share Price||Market Cap|
|Extraction + CPGs + Psychedelic Mental Health||$0.32||$24.1M|
|The Valens Company||OTC:VLNCF TSX:VLNS||Extraction + CPG + Analytical Testing||$1.93||$287.9M|
|Psychedelic Mental Health||$2.43||$790.9M|
|COMPASS Pathways||NASDAQ:CMPS||Psychedelic Mental Health||$35.95||$1.32B|
|Neptune Wellness Solutions||NASDAQ:NEPT|
|Cannabis Extraction and CPGS||$1.25||$208M|
|Numinus Wellness||OTC:LKYSF TSXV:NUMI||Psychedelic Mental Health||$0.76||$151.5M|
*Latest share price taken from Yahoo! Finance on April 14, 2021
**All prices in USD
MILESTONES AND TIMELINE
Pure Extracts’ Management Team
Leading Pure Extracts Corp. (OTC: PRXTF / CSE: PULL / XFRA: A2QJAJ) is a team that brings an exceptional range of experience in cannabis, agriculture, natural products, the beverage and alcohol space, and building publicly-traded companies.
Chief Executive Officer – Ben Nikolaevsky
Nikolaevsky has +10 years’ experience in corporate leadership roles across the natural products, agriculture and cannabis sectors. Under his recent leadership as President & CEO of Natura Naturals Inc., a private Canadian cannabis licensed producer, the company was acquired by Tilray Inc. Prior to Natura, he was president & CEO of Blue Goose Capital Corp. He has also served as Market Vice President, National Accounts at CIBC and as Chief Credit Officer & Capital Markets Manager at IBM Global Financing Canada.
Chief Operations Officer, Founder – Doug Benville
Benville has +10 years of experience in the cannabis space, where he developed a high proficiency in cannabis cultivation, system operations and oil extraction. He’s been with Pure Extracts since its inception and is the founder of the Pure Pulls brand—one of the most recognized extract brands in Canada.
Vice President of Busines Development – Alexander Logie
Logie is a serial entrepreneur with +30 years’ experience in the financial services sector. He co-founded Crane Capital and Mercury Capital, both successfully acquired by asset management firms. Logie recently held the position of interim CFO, acting COO and SVP of Business Development at Natura Naturals Inc., a private licensed producer of cannabis that was acquired by Tilray Inc. at the start of 2019.
Vice President of Sales – Andy Gauvin
Gauvin is an accomplished, bilingual, senior sales leader that brings +30 years’ experience in the Cannabis & Beverage Alcohol space. Most recently, he was the Vice President of Sales with a start-up licensed producer, Natura Naturals. He established relationships with key provincial cannabis customers, developed sales strategies and played an important role in product development. In his previous role as VP of Sales Canada, with Moosehead Breweries, he built and developed a National Sales Strategy that incorporated all of the unique aspects from each province including jurisdiction P&L, formal sales management and built a sales culture that held sales people accountable and focused on results.
Head of Quality Assurance – Shivani Bhatia
Prior to joining Pure Extracts, Bhatia held a senior position at Whistler Medical Marijuana Corp. handling Quality Assurance work for two facilities. A Health Canada Security Cleared QA professional, Shivani established and enforced GPP, GMP, and Quality Assurance standards. She holds a Bachelor of Science in Biotechnology, a Master of Science in Biotechnology and a post graduate diploma in Pharmaceutical Research.
8 REASONS Why Pure Extracts is primed to Capitalize on the Upcoming Extraction Boom:
- Focused on Extraction and Production of CPGs and ingredients from cannabis/hemp and functional mushrooms.
- High margin and growth from modern CO2 and ethanol extraction capabilities represents the highest margin sector of the Canadian cannabis industry, and one of the most expensive input costs of the psilocybin research market.
- Seasoned management team with highly technical experience in extraction and successful sales of companies.
- Nationally recognized brand and International expansion with the popular line of Pure Pulls vape pens has already won a loyal consumer base.
- US expansion to Michigan, one of the most important and fastest growing US markets where sales of recreational cannabis in February were up +160% from last year.
- Impressive Scale that aims for a capacity of over 100,000 kg of biomass per year, with a technique that has been tried and tested through the team’s industry experience.
- Near-term revenue as soon as full licensing is obtained, as milestone licenses have already been granted.
- M&A and international growth opportunities due to a facility design geared towards EU GMP standards, and a signed agreement for Canadian and International rights for a new line of gummies with the manufacturer of a major US alcohol company’s branded cannabis products.
Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Flyonwallstreet.com is a wholly-owned subsidiary of Maynard Communication Limited (“MCL”). MCL has been paid a fee for Pure Extracts Technologies Corp. advertising and digital media from the company directly. This fee constitutes cash and 3 Million Common Shares that were paid to MCL as a part of a finders fee; shares we have purchased in the open market. There may be other 3rd parties who may have shares of Pure Extracts Technologies Corp., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MCL own shares of Pure Extracts Technologies Corp. as noted above. MCL will not buy or sell shares of Pure Extracts Corp. for a minimum of 72 hours from the publication date on this website November 3, 2020, but reserve the right to buy and sell, and will buy and sell shares of Pure Extracts Technologies Corp. commencing immediately after said publication date without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MCL has been approved by Pure Extracts Technologies Corp.; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through private placements and/or other investment vehicles.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.